# The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

> **NCT01679080** · PHASE2 · TERMINATED · sponsor: **University of Aarhus** · enrollment: 9 (actual)

## Conditions studied

- Osteogenesis Imperfecta

## Interventions

- **DRUG:** Zoledronic acid
- **DRUG:** Teriparatide
- **OTHER:** No active treatment

## Key facts

- **NCT ID:** NCT01679080
- **Lead sponsor:** University of Aarhus
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2020-07-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Eli Lilly has withdrawn support to the study of teriparatide and placebo pens. The study was not able to continue as a randomized study without the supply of placebo pens.
- **Last updated:** 2021-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01679080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01679080, "The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01679080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*